AI drug discovery company Iambic has raised $150 million through an initial public offering, according to a Techub News brief citing Tech in Asia. Nvidia is listed as one of the company’s investors. Iambic said the proceeds will be used to move forward three early-stage cancer drug candidates. The update centers on the company’s fundraising and planned use of capital, without disclosing additional offering terms in the source text. The report frames the transaction as a financing event tied to Iambic’s drug development pipeline.
AI drug discovery company Iambic raised $150 million through an initial public offering, according to Techub News, which cited Tech in Asia. Nvidia is one of the company’s investors.
Iambic said the funds will be used to advance three early-stage cancer drug candidates.
This article was originally published by Bit.Fan. For more cryptocurrency news and market insights, visit www.bit.fan. Disclaimer:
The market information, project data, and third-party content displayed on this platform are for industry information sharing only and do not constitute any form of investment advice or return commitment.
Cryptocurrency trading carries high risks. Users should fully assess their risk tolerance and make independent decisions. All profits, losses, and legal responsibilities are borne by the users themselves.
